Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sirolimus to Vascular Anomalies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients included in the present research must be diagnosed with one of the following vascular anomalies:~  1. Kaposiform Hemangioendotheliomas without Kasabach-Merritt Phenomenon~ 2. Tufted Angioma without Kasabach-Merritt Phenomenon~ 3. Capillary Malformations~ 4. Lymphatic Malformations~ 5. Venous Malformations~ 6. Capillary-Venous Malformation (CVM)~ 7. Capillary-Lymphatic Malformation (CLM)~ 8. Lymphatic-Venous Malformation (LVM)~ 9. Capillary-Lymphatic-Venous Malformation (CLVM)~ 10. Multifocal Lymphangiomatosis and Thrombocytopenia (MLT)~* Patients must be 0 - 18 years of age at the time of study entry.~* Without functional impairment requiring treatment of corticosteroid.~* Organ function requirements:~* Adequate liver function Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)for age, and alanine transaminase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 x upper limit normal (ULN) for age.~* Adequate renal function 0-5 years of age maximum serum creatinine (mg/dL) of 0.8 6-10 years of age maximum serum creatinine (mg/dL) of 1.0 11-15 years of age maximum serum creatinine (mg/dL) of 1.2 16-18 years of age maximum serum creatinine (mg/dL) of 1.5~* Adequate bone marrow function:~Absolute Neutrophil Count (ANC) greater than or equal to 1 x 10 to the ninth/Liter~* Consent of parents (or the person having parental authority in families): Signed and dated written informed consent.~Exclusion Criteria:~* Allergy to sirolimus or other rapamycin analogues.~* Allergy to sirolimus or other rapamycin analogues.~* Any known evidence of significant local or systemic uncontrolled infection, defined as receiving intravenous antibiotics at the time of randomization.~* Patients must not be known to be Human Immunodeficiency Virus positive or known immunodeficiency. Testing is not required unless a condition is suspected.~* Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (e.g. uncontrolled diabetes, uncontrolled hypertension, severe malnutrition, chronic liver or renal disease, active upper gastrointestinal tract ulceration).~* Impairment of gastrointestinal function or chronic gastrointestinal disease that may significantly alter the absorption of sirolimus.~* Patients who have a history of malignancy.~* Patients with an inability to participate or to follow the study treatment and assessment plan.~* Patients who have a history of treatment with sirolimus or other mTOR inhibitor.

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Sirolimus (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).